A Multicenter, Randomized, Double-blind, Three-arm, Parallel Clinical Endpoint Bioequivalence Study of Monometasone Furoate Nasal Spray in Patients With Seasonal Allergic Rhinitis
Conditions: Seasonal Allergic Rhinitis Interventions: Drug: Mometasone furoate as a nasal spray Sponsors: Zheng Liu ENT; Zhejiang Xianju Pharma Tech. Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2024 Category: Research Source Type: clinical trials
Azelastine Allergen Chamber - Onset of Action Study
Conditions: Seasonal Allergic Rhinitis Interventions: Drug: Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair); Drug: Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray; Drug: Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray Sponsors: MEDA Pharma GmbH& Co. KG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2023 Category: Research Source Type: clinical trials
Role of Lung Function for Exercise Capacity in Well-trained Individuals
Conditions: Exercise Performance Interventions: Drug: Vilanterol and Fluticasone Furoate; Drug: Indacaterol and Mometasone Furoate; Drug: Placebo Sponsors: Morten Hostrup, PhD Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 11, 2023 Category: Research Source Type: clinical trials
Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis
Condition: Seasonal Allergic Rhinitis Interventions: Drug: Mometasone + Azelastine; Drug: Mometasone Furoate; Drug: Azelastine Hydrochloride Sponsor: Sandoz Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma
Condition: Asthma Interventions: Drug: QVM149; Drug: Salmeterol Xinafoate / Fluticasone Propionate; Drug: Placebo to QVM149; Drug: Placebo to Salmeterol Xinafoate / Fluticasone Propionate; Drug: Run-In Medication; Drug: Rescue Medication; Device: Concept 1 Device; Device: Girohaler Sponsor: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2023 Category: Research Source Type: clinical trials
